Cardiol Therapeutics Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- David G. Elsley
- Full Time Employees
- 18
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- 2265 Upper Middle Road East Oakville ON Canada L6H 0G5
- IPO Date
- Jan 15, 2019
- CIK
- 0001702123
- Website
- cardiolrx.com
- Similar Companies
- Business
- Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's core products include CardiolRx, an oral pharmaceutically manufactured cannabidiol formulation, targeting rare cardiac conditions such as recurrent pericarditis and acute myocarditis, and CRD-38, a novel subcutaneously administered cannabidiol formulation for inflammatory heart diseases including heart failure. CardiolRx aims to modulate inflammasome pathway activation to reduce inflammation and fibrosis in the heart, representing a potential disease-modifying, non-immunosuppressive treatment option. Recent major developments include positive Phase II ARCHER trial results demonstrating significant improvements in cardiac structure and function in patients with acute myocarditis, ahead-of-schedule patient enrollment completion for this trial, advancement of the Phase III MAVERIC trial in recurrent pericarditis, and a Notice of Allowance from the US Patent and Trademark Office covering cannabidiol compositions for cardiac treatments protecting CardiolRx and CRD-38 through 2040. The company raised $11 million via a private placement in 2025 to support its clinical pipeline and received a Buy rating with a price target of $6.00 by Brookline Capital Markets. Cardiol Therapeutics operates primarily in Canada and the United States and is headquartered in Toronto, Canada. Founded in 2014, it collaborates with international research institutions including Tecnológico de Monterrey and the DeBakey Heart and Vascular Center in Houston for development of its therapies targeting inflammation and fibrosis in cardiovascular diseases.
Cardiol Therapeutics to Participate in Fireside Chat at H.C. Wainwright 4th Annual BioConnect Investor Conference at the NASDAQ
Cardiol Therapeutics' Phase II MAvERIC Results Accepted for Publication in the Journal of the American Heart Association
Cardiol Therapeutics Expands U.S. MAVERIC Phase III Trial Network to Address Growing Interest in the Pivotal Program
Contrasting Corcept Therapeutics (NASDAQ:CORT) & Cardiol Therapeutics (NASDAQ:CRDL)
Cardiol Therapeutics to Highlight MAVERIC Phase III Trial and Recently Published ARCHER Results in Live Interview with Barchart
Cardiol Therapeutics Announces Year-End 2025 Update on Operations
Cardiol Therapeutics Touts Phase III MAVERIC Timeline for CardiolRx at TD Cowen Healthcare Conference
Cardiol Therapeutics to Present at TD Cowen 46th Annual Health Care Conference
Cardiol Therapeutics' ARCHER Phase II Study Results Published in ESC Heart Failure
Cardiol Therapeutics (TSE:CRDL) Shares Down 7.1% – Time to Sell?
Cardiol Therapeutics (TSE:CRDL) Shares Down 7.1% – What’s Next?
Cardiol Therapeutics Announces Closing of Bought Deal Financing and Full Exercise of Over-Allotment Option for Gross Proceeds of $14.85 Million
Cardiol Therapeutics Announces Bought Deal Financing for Gross Proceeds of $13.5 Million
Cardiol Therapeutics Inc. Announces Bought Deal Financing for Gross Proceeds of $13.5 Million
Cardiol Therapeutics Achieves Key 50% Patient Enrollment Milestone in Pivotal Phase III MAVERIC Trial in Recurrent Pericarditis
New Data from the Phase II ARCHER Trial Demonstrate CardiolRx(TM) Improves Heart Structure in Patients with Acute Myocarditis, Supporting Expansion Across Inflammatory Cardiac Conditions
Cardiol Therapeutics (TSE:CRDL) Trading Down 3.5% – What’s Next?
Cardiol Therapeutics Receives U.S. Patent Allowance Broadly Protecting its Heart Drugs to Late 2040
Cardiol Therapeutics' Phase II ARCHER Trial Results to be Presented at the European Society of Cardiology Scientific Meeting on Myocardial & Pericardial Diseases
Cardiol Therapeutics Completes US$11.4 Million Financing and Extends Cash Runway into Q3 2027